Full Press Release Details
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November.
Details are as follows:
Guggenheim 2nd Annual Healthcare Innovation ConferenceLocation:Boston, MADate:Monday, November 10, 2025Time:3:30 PM ETWebcast Link:https://event.summitcast.com/view/6h3HS7z68WnTQE5PS7Vq8J/Whrfp7V7J4xxPSb6WEtmkp
Stifel 2025 Healthcare ConferenceLocation:New York, NYDate:Wednesday, November 12, 2025Time:4:00 PM ETWebcast Link:https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/PK2LUcfo5tANjQo7JVHDsB
Jefferies Global Healthcare ConferenceLocation:London, UKDate:Thursday, November 20, 2025Time:12:00 PM GMTWebcast Link:https://wsw.com/webcast/jeff332/cmpx/1860808
Virtual/Replay availability:Presentations will be archived for 90 days on Compass’Eventspage.
About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.